GHENT, Belgium, Feb. 19, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] will announce its full year results for 2014 on Thursday 26 February 2015 at 7.00 am CET.
The Ablynx management team will host a conference call and webcast during which the full year results for 2014 will be presented, followed by a Q&A session. This event will be held on Thursday 26 February 2015 at 3.00 pm CET/09.00 am EST.
The conference call will be webcast live and may be accessed on the homepage of the Ablynx website at www.ablynx.com or by clicking here. If you would like to participate in the Q&A session, please dial +32 (0)2 404 06 62, confirmation code 9002858. Shortly after the call, a replay of the webcast and copy of the presentation will be available on the Ablynx website under the news & events>past events page.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations and significant partnerships with pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Jonathan Birt, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
pdf version of the press release http://hugin.info/137912/R/1895496/672191.pdf